The global endometrial cancer treatment market size was valued at USD 26.8 billion in 2021 and growing at a CAGR of 4.8% during 2022-28. Endometrial cancer, often known as uterine cancer, is one of the most prevalent gynecological malignancies, with 2.8 percent of women developing it at some time in their life. Endometrial cancer accounted for 1.8 percent of all malignancies in 2015, as per National Cancer Institute figures, and 3.6 percent of all new cancer cases were identified as endometrial cancer. Endometrial cancer can be detected early, which aids in the selection of appropriate treatment choices. Endometrial malignancies are classified as type I or type II tumors, and the vast majority of individuals identified with endometrial cancer are in the early stages of the disease. As per Yale University School of Medicine in the United States, type I tumors account for 80% of all endometrial cases of cancer identified in the United States in 2014.

View Detailed Report Description at        

Increased knowledge of uterine illnesses and accessible therapies, innovation in developing drugs and consequent technical improvements, and rising healthcare spending are all factors driving the endometrial cancer market. For example, in most nations, healthcare spending is growing faster than economic growth, a pattern that has been seen for decades. The presence of egalitarian, adaptive, and effectiveness and organizational systems in North America, Europe, and Asia-Pacific nations has also led to the highest percentage of GDP being used for health care. Furthermore, as the number of individuals diagnosed with cancer rises, the introduction of new treatments is likely to raise cancer care expenses. Cancer treatment may be prohibitively expensive, especially for patients and sufferers who require long-term care and supervision. Furthermore, appealing healthcare insurance plans and improved reimbursement rates are anticipated to drive the demand analyzed by raising people's spending on treatments. Moreover, market expansion is likely to be hampered by issues also including treatment side effects and excessive medication toxicity.

The Endometrial Cancer market is fragmented on the basis of Type of Cancer, which is further bifurcated into Uterine Sarcomas and Endometrial Carcinoma. The market is also categorized into Diagnosis Method, Type of Therapy, and Region.

Due to a high prevalence of uterine serous carcinoma, North America presently leads the endometrial cancer market and is anticipated to remain so for a several more years. The United States has the biggest market share in North America. This is mostly due to an increase in the occurrence of endometrial malignancies. This, coupled with other factors such as increasing cancer awareness and the availability of a well-developed healthcare infrastructure, is projected to drive the market in the United States forward.

Request sample report at                

There are several industry players working in the endometrial cancer treatment market, which include Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), Ariad Pharmaceuticals, Inc. (U.S.), GlaxoSmithKline Plc (U.K.), Hoffmann-La Roche AG (Switzerland), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), Siemens Healthcare GmbH (Germany), Sanofi (France)


About Precision Business Insights:

We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.


Precision Business Insights offers a variety of cost-effective and customized research services to meet research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.



Mr. Satya

Precision Business Insights | Toll Free: +1 866 598 1553

Email: [email protected]
Kemp House, 152 – 160 City Road, London EC1V 2NX
Web: | D U N S® Number: 852781747